Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Wednesday's Featured Story 3 Biotech Stocks That Look Like "Sure-Fire" Winners in 2026Reported by Chris Markoch. First Published: 1/20/2026. 
In Brief - Eli Lilly leads the GLP-1 market while advancing late-stage drugs in Alzheimer’s, oncology, and cardiovascular disease.
- Viking Therapeutics offers a high-upside GLP-1 challenger supported by strong trial data and institutional ownership.
- Biogen provides exposure to neurodegenerative disease breakthroughs at a valuation below its historical averages.
The words “sure-fire” and biotechnology stocks rarely go together. This sector carries above-average risk: a company's fate often hinges on clinical trial results, regulatory decisions and its ability to scale approved drugs. Even promising programs can fail or face long delays. Still, a single FDA approval can generate outsized returns. Many biotech names begin as penny stocks, so finding a winner can feel like buying a lottery ticket—yet that potential payoff keeps investors hunting for opportunities in the space. AI is creating 1,600 new millionaires every single day. At the center of this frenzy sits Nvidia, now valued at $4.5 trillion. But most investors don't know Nvidia has three secret partners, smaller companies that play almost impossible-to-replicate roles in GPU development. Without them, Nvidia's business would be hamstrung. Because they're largely ignored, these companies trade at far more attractive valuations, giving you a way to capitalize on Nvidia's dominance without buying Nvidia itself. This is a pivotal moment for AI, but winning this trend requires playing smart, not reckless. See the full 2026 AI investment playbook and all three secret partners. At first glance, the three companies below may look conservative for growth investors. But for reasons explained here, each could offer meaningful upside in 2026. Eli Lilly: The Large-Cap Anchor With More Growth to Come The first name is Eli Lilly & Co. (NYSE: LLY), the leader in the growing GLP-1 market and a dominant player in two of the largest drug markets: obesity and diabetes. Zepbound and Mounjaro alone keep Lilly firmly in the spotlight. Demand for GLP-1 therapies continues to outstrip supply, and because obesity drugs are typically long-term treatments rather than one-off fads, Lilly's total addressable market (TAM) should expand. Also supporting the case for LLY are late-stage candidates in Alzheimer's disease, oncology and cardiovascular disease. LLY stock traded above $1,000 per share as of Jan. 16, which may put it out of reach for some investors. Even with a price-to-earnings (P/E) ratio near 50x, Lilly has carried higher valuations in recent years. Analysts forecast earnings growth of more than 32% this year, a pace that could support a notably higher stock price over time. Viking Therapeutics: A Mid-Cap Stock That Could Be a Worthy Challenger If LLY still feels too expensive, consider Viking Therapeutics Inc. (NASDAQ: VKTX). The company has both oral and injectable GLP-1 candidates in late-stage trials, and early-stage data have shown promising weight-loss results. There's no obvious dethroner to Lilly today, but the market is desperate for competition. If Viking's candidates clear trials, the company could become an attractive acquisition target. Analysts have a consensus price target of $87.14 for VKTX, roughly a 155% increase from its closing price on Jan. 16. Institutional ownership exceeds 70%, signaling confidence from larger investors. Biogen: May Be on the Brink of Breakthroughs for High-Impact Diseases Beyond GLP-1s, many investors are hunting for the next major innovation — treatments for Alzheimer's and other neurodegenerative diseases, where current options are limited and unmet need is high. Biogen Inc. (NASDAQ: BIIB) provides a direct way to gain exposure to that area, with multiple neurodegenerative candidates in its pipeline. As noted earlier, a single successful program can produce sizable returns for shareholders. BIIB stock is up roughly 16% over the past 12 months, including a 14% gain in the three months through Jan. 16. Analysts project further upside, with a consensus price target of $190.50, about 15% above the current level. At around 10x forward earnings, Biogen also looks attractively valued heading into the year.
| 
Post a Comment
Post a Comment